SequelSEC

Zeo ScientifiX, Inc. ZEOX

Biological Products, (No Diagnostic Substances) · CIK 0001557376 · Fiscal year ends 1031

AnnualQuarterlyTTM
Revenue
$6.99M
Fiscal year ended 2026-04-30
Operating income
-$4.13M
Fiscal year ended 2026-04-30
Free cash flow
Unavailable
Fiscal year ended 2026-04-30

Valuation, from the filing

Public float$7.13MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-04-30
Float per share$0.94Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue1.4×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-04-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-10-31 — the year that filing covered.

How this compares in its industry

Percentile among the Biological Products, (No Diagnostic Substances) filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
R&D / revenue1.9%2th
Current ratio0.33x10th
CapEx / revenue0.4%12th
FCF margin-14.3%77th
Operating margin-103.6%69th
Net margin-106.2%66th
SBC / revenue90.3%66th
Gross margin82.1%66th
Revenue YoY growth12.5%55th

Zeo ScientifiX, Inc. (ZEOX) reported revenue of $6.99M and net income of -$3.88M for the fiscal year ended 2026-04-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Zeo ScientifiX, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

Zeo ScientifiX, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-04-30
Revenue$6.99M
Cost of revenue$1.29M
Gross profit$5.70M
Operating income-$4.13M
Net income-$3.88M
Research & developmentUnavailable
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$9.82M
Selling & marketingUnavailable

Balance

Zeo ScientifiX, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-04-30
Cash & equivalentsUnavailable
Total assets$3.89M
Current assets$3.27M
Total liabilities$3.17M
Current liabilities$3.11M
Total equity incl. NCI$712.00K
Temporary (mezzanine) equityUnavailable
Inventory$686.00K
Accounts receivable$276.00K
GoodwillUnavailable
Long-term debtUnavailable
Accounts payableUnavailable

Cash flow

Zeo ScientifiX, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-04-30
Operating cash flow-$1.25M
Capital expendituresUnavailable
Investing cash flowUnavailable
Financing cash flow$2.28M
Net change in cashUnavailable
Stock-based compensation$3.69M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$77.00K

Derived

Zeo ScientifiX, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-04-30
Free cash flowUnavailable
Gross margin81.5%
Operating margin-59.1%
FCF marginUnavailable
SBC / revenue52.8%
Current ratio1.05x
Revenue YoY growth52.8%
Net margin-55.6%
R&D / revenueUnavailable
CapEx / revenueUnavailable
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ZEOX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-06-15View SEC filing
10-Q · Filed 2026-03-17View SEC filing
10-K · Filed 2026-01-29View SEC filing
10-Q · Filed 2025-09-15View SEC filing
10-Q · Filed 2025-06-16View SEC filing
10-Q · Filed 2025-03-17View SEC filing

Companies in the same industry

ABOS ABPO ACOG ADAPY ADMA ADPT AGEN AGTX AIM ALEC ALGS ALLO

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.